Zynex Inc (ZYXI) Stock
ZYXI is no longer traded. Zynex was delisted from the Nasdaq in February 2026.
Prices on this page are historical; the last trade was February 24, 2026 at $0.09.
Zynex stock price history
ZYXI final trading statistics
- Final close
- $0.09
- Final trading day
- Feb 24, 2026
- Market cap at delisting
- $2.61M
- Shares outstanding
- 30.39M
- Final 52-week range
- $0.02 – $7.58
- Avg. volume (final 3 mo.)
- 4,067,704
- All-time high (split-adj.)
- $29583.18 · Jun 2000
- All-time low (split-adj.)
- $0.03 · Feb 2026
- Return since IPO
- -100.0%
- Beta
- 1.00
- Book value / share
- -$1.34
- Price / book
- -0.06
Zynex annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $192.35M | $3.0M | $0.09 |
| FY2023 | $184.32M | $9.7M | $0.44 |
| FY2022 | $158.17M | $17.0M | $0.44 |
| FY2021 | $130.30M | $17.1M | $0.43 |
| FY2020 | $80.12M | $9.1M | $0.25 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Zynex Inc
Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain, and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; and M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body; and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, braces for rehabilitation support for knee and wrist, and Dynacomp for cold compression therapy. Further, it develops Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser photoplethysmographic patient monitoring device; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; and fluid monitoring and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado. On December 15, 2025, Zynex, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas.
Zynex stock FAQ
What happened to Zynex stock?
Zynex stock was delisted from the Nasdaq. Its final close was $0.09 on February 24, 2026.
Is ZYXI stock still trading?
No. ZYXI was delisted from the Nasdaq in February 2026 and no longer trades on a U.S. exchange.
What was the last price of ZYXI stock?
ZYXI closed at $0.09 on its final trading day, February 24, 2026, for a market value of about $2.61M.
What were Zynex's revenue and earnings in its last full fiscal year?
Zynex reported revenue of $192.35M and net income of $3.0M in fiscal 2024, its last full year as a public company.
When did Zynex go public?
Zynex Inc stock began trading on December 31, 2002.